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OBJECTIVE — To investigate the inﬂuence of primary graft function (PGF) on graft survival
and metabolic control after islet transplantation with the Edmonton protocol.
RESEARCHDESIGNANDMETHODS — Atotalof14consecutivepatientswithbrittle
type 1 diabetes were enrolled in this phase 2 study and received median 12,479 islet equivalents
per kilogram of body weight (interquartile range 11,072–15,755) in two or three sequential
infusions within 67 days (44–95). PGF was estimated 1 month after the last infusion by the
-score, a previously validated index (range 0–8) based on insulin or oral treatment require-
ments, plasma C-peptide, blood glucose, and A1C. Primary outcome was graft survival, deﬁned
as insulin independence with A1C 6.5%.
RESULTS — All patients gained insulin independence within 12 days (6–23) after the last
infusion.PGFwasoptimal(-score7)inninepatientsandsuboptimal(-score6)inﬁve.At
last follow-up, 3.3 years (2.8–4.0) after islet transplantation, eight patients (57%) remained
insulin independent with A1C 6.5%, including seven patients with optimal PGF (78%) and
one with suboptimal PGF (20%) (P  0.01, log-rank test). Graft survival was not signiﬁcantly
inﬂuenced by HLA mismatches or by preexisting islet autoantibodies. A1C, mean glucose,
glucose variability (assessed with continuous glucose monitoring system), and glucose toler-
ance (using an oral glucose tolerance test) were markedly improved when compared with
baseline values and were signiﬁcantly lower in patients with optimal PGF than in those with
suboptimal PGF.
CONCLUSIONS — Optimal PGF was associated with prolonged graft survival and better
metabolic control after islet transplantation. This early outcome may represent a valuable end
point in future clinical trials.
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T
he short-term effectiveness of islet
transplantation for alleviating hypo-
glycemia and controlling glucose
homeostasis while limiting or even avoid-
ing the need for exogenous insulin has
been established (1). Despite protocol
modiﬁcations in donor selection, islet
preparation, or recipient treatment, insu-
lin independence with adequate meta-
bolic control was, however, rarely
prolonged beyond 2 years (1–5). The
most frequently proposed explanations
include chronic allogenic rejection, re-
currence of autoimmunity, and -cell
toxicityfromadministeredimmunosup-
pressive drugs (6). It is, however, unclear
why similar drawbacks do not preclude
the more durable results of pancreas
transplantation (7). Alternatively, a
slightly impaired glucose control associ-
ated with suboptimal graft function, even
in patients with apparently successful is-
let transplantation, could contribute to
progressive islet exhaustion and precipi-
tate graft decline (6). In this prospective
longitudinal study, we explored this hy-
pothesisbyanalyzingtheinﬂuenceofpri-
mary graft function (PGF) on graft
survival and metabolic control in a con-
secutivecohortof14patientsfollowedup
for 2 years and beyond after islet trans-
plantation with the Edmonton protocol.
RESEARCH DESIGN AND
METHODS— A total of 14 patients
wereenrolledinthissingle-centerphase2
trial initiated in 2003 after approval by an
institutional review board and the French
health agency (Agence Franc ¸aise de Secu-
rite Sanitaire des Produits de Sante ´). Eli-
gible patients were male or female aged
18–65 years, with type 1 diabetes docu-
mented for more than 5 years, arginine-
stimulated C-peptide 0.2 ng/ml, and
hypoglycemia unawareness or docu-
mented metabolic lability. Exclusion cri-
teriaincludedaBMI28kg/m
2,unstable
arteriopathy or heart disease, active infec-
tion, previous transplantation, insulin
daily requirements 1.2 units/kg, creati-
nine clearance 60 ml/min per 1.73 m
2
or urinary albumin excretion 300 mg/
day, malignancy, smoking, desire for
pregnancy, psychiatric disorders, and
lackofcompliance.Thestudyprimaryef-
ﬁcacyendpointwasgraftsurvivaldeﬁned
as insulin independence and A1C
6.5%. Secondary outcomes were graft
function and metabolic control.
Islet transplantation
Islet transplantation consisted of up to
three sequential fresh islet infusions
within3months,withtheaimofreaching
adequatemetaboliccontrolwithoutexog-
enous insulin. Islets were isolated from
ABO-compatible deceased donor pancre-
ata with a negative cross-match and eval-
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accesstotheportalveinwasgainedunder
general anesthesia by percutaneous cath-
eterization of a peripheral portal branch
under ultrasound guidance or by surgical
catheterizationofasmallmesentericvein.
In all cases, heparin (35 units/kg) was
added to the ﬁnal product, gently infused
by gravity with portal pressure monitor-
ing. Immunosupression consisted of ta-
crolimus (Prograf) (Astellas, Fujisawa,
Japan), target trough levels at 3–6 ng/ml,
and sirolimus (Rapamune) (Wyeth Phar-
maceuticals France, Paris, France), target
troughlevelsat12–15ng/mlfor3months
and at 7–10 ng/ml thereafter. A ﬁve-dose
induction course of dacluzimab (Zena-
pax) (1 mg/kg) (Roche, Welwyn Garden
City, U.K.) was administered biweekly
beginning 1 h before the ﬁrst infusion.
Follow-up
Patients were seen weekly during 1
month after each islet infusion, monthly
during the 1st year, and every 6 months
thereafter for routine clinical and biolog-
ical evaluation, including fasting blood
glucose,basalandpostprandialplasmaC-
peptide, A1C, and sirolimus and tacroli-
mus trough levels. Quarterly, glucose
variability was assessed over 3 consecu-
tive days with a continuous glucose mon-
itoring system (CGMS) (Medtronic
MiniMed, Northridge, CA). At each an-
nual visit, an oral glucose tolerance test
(OGTT) (75g) was performed in patients
who remained insulin independent to as-
sess glucose tolerance as proposed by the
American Diabetes Association (9). The
presence and type of autoantibodies (in-
sulinoma-associated protein 2 [IA2],
GAD, and islet cell antibody [ICA]) and
panel-reactive anti-HLA (A, B, and DR)
antibodies were evaluated before trans-
plantation, after each islet infusion,
yearly during follow-up, and, in case of
graft loss, 3 months after discontinua-
tionofimmunosuppression.Exogenous
insulin was reintroduced when A1C in-
creased 6.5% on two consecutive
measurements.
Outcomes
Graft function was estimated with the
-score,apreviouslyvalidatedcomposite
index ranging from 0 (no graft function)
to 8 (excellent graft function) (2). The
-score was calculated as initially de-
scribed by Ryan et al. (2), giving two
points for normal fasting glucose (5.5
mmol/l), A1C (6.1%), stimulated
and/or basal C-peptide (0.3 nmol/l),
and absence of insulin or oral hypoglyce-
mic agent use. No point was awarded if
fasting glucose was in the diabetic range
(7 mmol/l), A1C was 6.9%, C-
peptide secretion was undetectable on
stimulation, or daily insulin use was
0.24 units/kg. One point was given for
intermediate values. Graft function was
consideredoptimalwhenthe-scorewas7
or 8, suboptimal when the -score was 4
to 6, or poor when the -score was 3 or
less. The primary graft function was de-
ﬁned for each patient as the -score cal-
culated at the ﬁrst monthly evaluation
after the last infusion. Metabolic control
outcomes were basal C-peptide, A1C,
mean glucose, glucose SD, and low glu-
coseexcursions(timewithglucose3.85
mmo/l) monitored by CGMS. Graft sur-
vival outcome was the loss of insulin in-
dependence and/or adequate metabolic
control (A1C 6.5%). Adverse events
were classiﬁed according to the National
Cancer Institute common terminology
criteria for adverse events (version 3.0);
grade 3–5 events were monitored.
Data analysis
Continuous variables were expressed as
median (interquartile range) or mean 
SD when indicated and were compared
using the Mann-Whitney U test, Wilcox-
on’ssigned-ranktest,orANOVAandpost
hocFisher’sprotectedleastsigniﬁcantdif-
ferences test, when appropriate. Categor-
ical variables were compared with the
Fisher’s exact test. The Kaplan-Meier es-
timates for graft survival outcomes were
made for the overall data and strata-
deﬁnedvariablesandcomparedusingthe
Mantel-Cox log-rank test. Correlations
wereassessedbylinearregression.Allcal-
culations were computed with Statview
(Abacus Concepts, Berkeley, CA). A P
level 0.05 was considered signiﬁcant.
RESULTS
Primary graft function
A total of 14 patients (supplementary Ta-
ble A1, available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc08-1685/DC1) received a
total of 38 islet preparations (supplemen-
taryTableA2)intwo(n4)orthree(n
10) infusions within a total period of 67
days (44–95). The last infusion had to be
postponed until day 140 in one patient
who experienced a 1-cm hepatic arterio-
venousaneurysmduringthesecondinfu-
sion and until day 186 in another patient
withprevioushistoryofbloodtransfusion
and HLA sensitization waiting for a com-
patible donor. All the patients gained in-
sulin independence 12 days (6–23) after
their last infusion. PGF estimated at the
ﬁrst posttransplant monthly evaluation,
36 days (27–45) following last infusion,
was optimal (-score 7 or 8) in nine pa-
tients(64%)andsuboptimal(-score6or
5) in ﬁve (36%) (Table 1 and supplemen-
tary Table A3). Patients who experienced
optimal PGF had slightly lower baseline
insulin requirements than patients with
suboptimal PGF (P  0.04), but the pre-
existence of islet autoantibodies and the
overall graft characteristics were not sta-




alive and none of the patients were lost to
follow-up, 39 months (32–48) after islet
transplantation. At 1 year, 10 patients
(71%) met the study primary end point.
At last follow-up, eight patients (57%) re-
mained insulin independent with ade-
quate metabolic control (A1C 6.5%)
2–5 years after islet transplantation. Six
patients had to return to small doses of
insulin and/or antidiabetic oral agents to
maintain optimal metabolic control 6–36
months after islet transplantation. Three
ofthemeventuallylostgraftfunction1,2,
and 12 months, respectively, after insulin
reintroduction and discontinued immu-
nosuppression. Figure 1 illustrates the
Kaplan-Meier estimates (95% CI) of the
proportion of patients with insulin inde-
pendenceandadequatemetaboliccontrol
and with persisting C-peptide secretion
(0.5 ng/ml) during follow-up. Graft
survival was signiﬁcantly inﬂuenced by
PGF(P0.01,log-ranktest).Conversely
thepresence(n8)orabsence(n6)of
islet autoantibodies before transplanta-
tion had no signiﬁcant inﬂuence on graft
survival (P  0.40, log-rank test).
Metabolic control
All metabolic parameters were signiﬁ-
cantly improved at 2 years and at last fol-
low-up when compared with baseline
values in the entire cohort of 14 patients
(intent-to-treat analysis). With the excep-
tion of low glucose excursions, these out-
comes were also markedly lower in
patients with optimal PGF than in those
with suboptimal PGF (Table 2). We also
analyzed the correlation between the val-
ues of -score and metabolic control out-
comesmeasuredthroughoutfollow-upin
the 14 patients before and after their
transplantation (n  92). By design, the
Graft function and survival after islet transplantation
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0.88; P  0.0001), fasting blood glu-
cose (r  0.88; P  0.0001), and C-
peptide (r  0.58; P  0.0001). This
score was also signiﬁcantly correlated
with the values of mean glucose (r 
0.65; P  0.0001), glucose SD (r 
0.62; P  0.0001), and low glucose
excursions (r  0.50; P  0.0001)
measured by CGMS. Furthermore, the
-score was correlated in insulin-
independent patients with 2-h postload
glucose level during OGTT (n  27) (r 
0.71; P  0.0001). A marked improve-
mentofmetaboliccontrolwasalreadyap-
parent during periods with suboptimal
graft function (Fig. 2). A1C, mean glu-
cose, and glucose SD were, however,
signiﬁcantly lower when graft function
was optimal (P  0.05 vs. suboptimal)
and reached 5.9  0.6%, 6.3  1.7
mmol/l, and 1.3  1.0 mmol/l, respec-
tively, in patients maintaining insulin
independence.
Safety
A total of 42 grade 3 or higher adverse
events were observed in 11 patients (0.9
event per patient year). Grade 4 events
(n  3) included one bile leak following
percutaneous infusion and one mechani-
cal bowel obstruction after surgical infu-
sion both requiring reintervention and
one neutropenia episode requiring
lenograstim treatment and discontinua-
tion of immunosuppression. Grade 3
events were expected and related to the
procedure (n  3) and/or the immuno-
suppression (n  36). The ﬁve most fre-
quent were neutropenia (n11), anemia
(n  5), diarrhea (n  4), elevated liver
enzymes (n  3), and increase of osteoar-
Table 1—Patient and graft characteristics
All patients Suboptimal PGF Optimal PGF P*
n 14 5 9
Sex (male/female) 7/7 4/1 3/6 0.09
Age (years) 42 (36–51) 42 (38–49) 42 (36–51) 0.99
Diabetes duration (years) 27 (17–31) 17 (15–27) 28 (26–34) 0.12
Weight (kg) 71 (61–78) 75 (69–79) 67 (60–76) 0.31
Baseline A1C (%) 8.5 (7.3–8.9) 8.7 (8.0–9.2) 8.3 (7.3–8.6) 0.35
Basal insulin requirements (units/kg per day) 0.53 (0.41–0.68) 0.68 (0.54–0.83) 0.42 (0.38–0.57) 0.04
Islet autoantibodies (yes/no) 9/5 4/1 5/4 0.18
Islet infusions (n) 3 (2–3) 3 (2.7–3) 3 (2–3) 0.61
First to last infusion (days) 67 (44–95) 60 (42–91) 73 (46–113) 0.74
Total islet mass (10
3 IEQ/kg) 12.5 (11.1–15.8) 12.6 (12.0–16.8) 11.5 (10.5–15.7) 0.46
Total islet number (10
3/kg) 14.4 (11.4–17.5) 15.2 (13.7–20.6) 13.4 (11.0–16.1) 0.59
Total -cell number (10
6/kg) 5.7 (5.0–12.9) 9.4 (2.6–16.3) 5.7 (5.1–10.1) 0.21
Total HLA mismatch (n) 6 (3–9) 9 (3–10) 5 (3–8) 0.63
Last infusion to insulin independence (days) 12 (6–23) 23 (0–61) 10 (6–22) 0.23
Initial A1C (%)† 5.6 (5.2–6.1) 6.3 (5.5–6.4) 5.3 (5.2–5.7) 0.38
Initial fasting blood glucose (mmol/l)† 5.7 (5.2–6.1) 6.5 (6.1–6.9) 5.2 (5.1–5.7) 0.38
Initial basal C-peptide (nmol/l)† 0.5 (0.41–0.53) 0.53 (0.5–0.53) 0.46 (0.4–0.5) 0.95




Patients with suboptimal PGF (n  5) Patients with optimal PGF (n  9)
Inclusion 2 years Last follow-up Inclusion 2 years Last follow-up
Insulin independence 0 (0) 1 (20) 1 (20) 0 (0) 8 (89)*† 7 (78)*†
A1C (%) 8.7 (8.0–9.2) 7.8 (7.4–8.7) 8.3 (7.4–9.4) 8.3 (7.3–8.6) 5.8 (5.4–6.5)*† 6.2 (5.6–6.7)*†
Mean glucose (mmol/l) 9.4 (7.5–12.4) 8.7 (6.3–10.6) 7.4 (6.3–10.6) 8.1 (6.5–11.6) 5.7 (5.4–6.1)*† 5.3 (5.1–5.6)*†
Glucose SD (mmol/l) 3.9 (3.0–4.9) 1.8 (1.4–4.4) 2.3 (1.6–4.4) 3.1 (2.2–4.4) 0.8 (0.7–1.0)* 1.0 (0.6–1.4)*†
Low glucose excursion (%) 9 (1–18) 0 (0–4) 3 (0–5) 16 (3–22) 0 (0–1)* 0 (0–0)*
Basal C-peptide (nmol/l) 0 (0–0) 0.17 (0–0.53) 0 (0–0.43) 0 (0–0) 0.5 (0.4–0.6)* 0.5 (0.43–0.6)*†
-Score (0–8) 0 (0–0) 1 (0–3.8) 2 (0–4.5) 0 (0) 7 (4.8–8)*† 7 (5.8–8)*†
Functioning graft 0 (0) 2 (40) 2 (40) 0 (0) 9 (100)*† 9 (100)*†
ADA criteria‡
Normal 0 (0) 1 (20) 0 (0) 0 (0) 5 (56)* 5 (56)*†
Glucose intolerance 0 (0) 0 (0) 0 (0) 0 (0) 2 (22) 4 (44)
Diabetes 5 (100) 4 (80) 5 (100) 9 (100) 2 (22) 0 (0)
Data are median (interquartile range) or n (%). *P  0.05 versus inclusion (Wilcoxon’s test); †P  0.05 versus suboptimal PGF (Mann-Whitney U test). ‡Deﬁned
by the American Diabetes Association (ref. 9); normal when fasting blood glucose was 5.6 mmol/l and 2-h postload glucose during OGTT was 7.8 mmol/l;
diabetes when fasting blood glucose was 7 mmol/l or 2-h postload glucose during OGTT was 11.1 mmol/l; and glucose intolerance when intermediate values.
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rum creatinine remained in the normal
range in all patients and the change from
baseline of creatinine clearance (esti-





2 (0.34 to 0.41) (increased in six pa-
tientsanddecreasedineight).Microalbu-
minuria (30 mg/day) persisted in one
patient and developed in ﬁve patients. At
the time of this report, no donor-speciﬁc
allosensitization has been detected using
lymphocytotoxicity test.
CONCLUSIONS — This prospective
cohort study showed that insulin inde-
pendence with adequate metabolic con-
trol can be maintained beyond 2 years
after islet transplantation in most recipi-
ents, when optimal graft function is ini-
tially achieved. Our results also suggest
that PGF plays a preeminent role in the
long-term outcome of islet transplanta-
tion. To assess graft function, we used the
-score, a composite index that was pre-
viously correlated with postprandial glu-
cose (10) and arginine-induced insulin
secretion (11) after islet transplantation.
In addition, we found herein a signiﬁcant
reciprocal relationship between the
-score and OGTT outcome as well as
with mean glucose and glucose variabil-
ity, two independent predictors of sec-
ondary complications in type 1 diabetic
patients (12). Most importantly, this sim-
ple index also allowed us to quantify PGF
after sequential islet transplantation.
With insulin independence and adequate
metabolic control in seven out of nine
cases(78%)andnormalglucosetolerance
in ﬁve (56%), the results observed after
islet transplantation in patients with opti-
malPGFmatchedbeyond2yearsthoseof
pancreas transplantation (7). The small
number of subjects enrolled is an obvious
limitationofourﬁndings,butthesimplic-
ity of the -score will allow their valida-
tion in other centers.
Noteworthy, we did not ﬁnd any sig-
niﬁcant inﬂuence of immunological
markers on PGF or graft survival. For its
limited power, this study does not ex-
clude the likely role also played by allo-
immunity (13) and autoimmunity (14) in
islet graft decline. Our results suggest,
however, that under the profound immu-
nosuppression induced by the Edmonton
protocol, the long-term outcome of islet
transplantation depends above all on
PGF. A similar long-term inﬂuence of
PGF is already established for kidney al-
lotransplantation(15).Besidesjustdelay-
ing graft loss, optimal kidney graft
function is associated with a decrease in
alloimmune graft impairment (16). Even
marginal hyperglycemia is deleterious for
-cells(17).Theimpairedmetaboliccon-
trol associated with suboptimal graft
function (Fig. 2) may have therefore di-
rectly contributed to islet decline in pa-
tients with lower PGF. Two independent
autopsy reports further support this non-
immunological mechanism of chronic is-
let impairment (18,19).
The risks associated with islet trans-
plantation appear limited compared with
those of pancreas transplantation (7).




proach for portal vein access and strictly
limiting the volume of infused tissue, we
avoidedhereinportalthrombosisandsig-
niﬁcant bleeding. However, we did not
eliminate adverse events related to the
procedure that required reintervention
after 2 of the 38 islet infusions (5%).
Other complications were expected (5)
and mainly related to chronic immuno-
Figure1—TheKaplan-MeierestimatesoftheproportionsofpatientswithinsulinindependenceandA1C6.5%(AandB)andwithpersistinggraft
function (basal C-peptide 0.5 ng/ml) (C and D). Left panels represent these proportions among the entire cohort (number at risk: 14 at baseline
and at 2 years, 7 at 3 years, and 3 at 4 years) and right panels in patients with optimal initial graft function (solid line) (n  9) and in those with
suboptimal initial graft function (interrupted line) (n  5). Circles indicate censored data. *Mantel-Cox log-rank test, optimal PGF vs. suboptimal
PGF.
Graft function and survival after islet transplantation
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we did not observe the early renal decline
reported elsewhere with the Edmonton
protocol (22). Renal impairment-like do-
nor-speciﬁc sensitization may, however,
emerge after a longer follow-up or when
assessed with more sensitive methods. It
cannot be fully excluded at this time in
our patients.
In summary, this study showed that
isletgraftsurvivalandadequatemetabolic
control can be markedly prolonged when
optimal graft function is initially achieved
and suggests that PGF has a preeminent
inﬂuence on long-term islet transplanta-
tion outcome. Whether this improved
metabolic control is sufﬁcient to over-
come the risks associated with chronic
immunosuppression will only be an-
swered by ongoing (21) and future con-
trolled studies comparing this procedure
with more established therapies. Our re-
sultssuggest,however,thatbesidesdevel-
oping new immunosuppressive strategies
withbettersafetyproﬁles,researchefforts
in islet transplantation should now focus
on optimizing PGF. In addition to in-
creasing the mass of transplanted islet
cells (23), signiﬁcant progress remains
necessary to improve islet potency (24)
andlimittheearlylossofisletsaftertrans-
plantation (25). PGF may serve as a valu-
able early end point to facilitate the
comparison of alternative strategies.
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